Literature DB >> 1832215

Interactions between adenovirus E1A and members of the AP-1 family of cellular transcription factors.

K Maguire1, X P Shi, N Horikoshi, J Rappaport, M Rosenberg, R Weinmann.   

Abstract

We have studied interactions between bacterially produced E1A linked to Sepharose and the various DNA-binding proteins present in HeLa cell nuclear extracts (NE). DNA-binding activities and cross-reactive polypeptides recognizing the cAMP-responsive element (CRE) and the activator protein 1 (AP1) sites were bound to the E1A column, whereas nuclear factor 1 (NF1) and the activator protein 2 (AP2) DNA-binding activities were not retained by E1A. The binding activities that were retained belonged to the CRE and JUN protein family, as judged by Western blot analysis. Authentic CRE-BP1, c-Jun and c-Fos proteins produced by in-vitro translation also bound to the E1A column. However, efficient binding of in-vitro-translated CRE-BP1 and c-Fos proteins to E1A required preincubation with NE. We show here that immobilized E1A sequesters several cellular upstream transcription activators, and suggest a role for members of the AP1 family of transcription factors in E1A-mediated gene regulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832215

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1.

Authors:  U Müller; T Kleinberger; T Shenk
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Transcriptional activation by the adenovirus larger E1a product is mediated by members of the cellular transcription factor ATF family which can directly associate with E1a.

Authors:  B Chatton; J L Bocco; M Gaire; C Hauss; B Reimund; J Goetz; C Kedinger
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

3.  An adenovirus E1A transcriptional repressor domain functions as an activator when tethered to a promoter.

Authors:  M Bondesson; M Mannervik; G Akusjärvi; C Svensson
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

4.  JNK1 is required for lentivirus entry and gene transfer.

Authors:  Meng-Horng Lee; Roshan Padmashali; Stelios T Andreadis
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  In vitro activation of transcription by the human T-cell leukemia virus type I Tax protein.

Authors:  M A Matthews; R B Markowitz; W S Dynan
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

6.  Transcription stimulation of the adenovirus type 12 E1a gene in vitro by the 266-amino-acid E1A protein.

Authors:  H Kawamura; N Wada; Y Makino; T A Tamura; S Koikeda; K Shiroki; Y Masamune; Y Nakanishi
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein.

Authors:  G Hateboer; H T Timmers; A K Rustgi; M Billaud; L J van 't Veer; R Bernards
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino-terminus-dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct-1 DNA binding activity.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Analysis of transcription factors binding to the duplicated PEA1 and PEA3 sites that are required for polyomavirus mutant expression in PCC4 embryonic carcinoma cells.

Authors:  J Y Nothias; R Weinmann; D Blangy; F Melin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors.

Authors:  M J Antinore; M J Birrer; D Patel; L Nader; D J McCance
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.